Introduction
Breast cancer remains a leading cause of cancer-related mortality worldwide, characterized by significant molecular heterogeneity. A key feature of its progression is metabolic reprogramming, where cancer cells alter their metabolic pathways to support rapid proliferation and survival. Central to this process is one-carbon metabolism, specifically the serine and glycine synthesis pathways. Serine hydroxymethyltransferase 2 (SHMT2), a mitochondrial enzyme, plays a pivotal role in these pathways. While the metabolic requirements for serine are well-documented, the broader regulatory influence of SHMT2 on cellular signaling and tumor progression in breast cancer has remained less understood. This study investigates how SHMT2 drives breast cancer growth and identifies the underlying molecular mechanisms.
Clinical Significance and Prognostic Value
To establish the clinical relevance of SHMT2, researchers analyzed its expression in 140 breast cancer patient tissue samples alongside matched adjacent normal tissues. The findings were further validated using public data from the TCPAC database. Immunohistochemistry and Western blotting revealed that SHMT2 is significantly overexpressed in breast cancer tissues compared to normal tissues. Crucially, high levels of SHMT2 expression were strongly correlated with poor overall survival ($p=0.005$), suggesting that SHMT2 could serve as a valuable prognostic biomarker for identifying high-risk patients.
Impact on Tumor Growth and Survival
The functional role of SHMT2 was explored through both loss-of-function and gain-of-function experiments. In vitro, silencing SHMT2 using shRNA significantly inhibited the growth of breast cancer cell lines (such as HCC1806 and ZR-75-1) and induced apoptosis. Conversely, in vivo experiments using subcutaneous xenograft mouse models demonstrated that SHMT2 overexpression markedly promoted tumor volume and weight over a 24-day period.
Transcriptomic analysis via RNA-seq further illustrated the scale of SHMT2’s influence. Overexpression resulted in the differential expression of 3,612 genes, impacting pathways related to serine metabolism, nucleotide metabolism, and oxidative phosphorylation. Beyond metabolism, SHMT2 was found to activate cell survival signaling while antagonizing apoptotic pathways.
Molecular Mechanisms: MAPK and VEGF Signaling
A primary discovery of this research is the link between SHMT2 and the MAPK signaling pathway. SHMT2 upregulation was found to increase the phosphorylation of ERK1/2 and p38. The importance of this connection was confirmed when the use of specific MAPK inhibitors (FR180204 and SB202190) partially reversed the growth-promoting effects of SHMT2.
Furthermore, SHMT2 appears to modulate the "angiogenic switch." High SHMT2 levels increased the secretion of Vascular Endothelial Growth Factor (VEGF), which promotes blood vessel formation, while decreasing Pigment Epithelium-Derived Factor (PEDF), an inhibitor of angiogenesis. This shift suggests that SHMT2 helps tumors recruit the blood supply necessary for sustained growth.
Finally, SHMT2 acts as a shield against programmed cell death. Its downregulation triggered the mitochondrial-mediated apoptosis pathway, characterized by the release of cytochrome-c and the activation of Caspase-3.
Conclusion
This study identifies SHMT2 as a critical driver of breast cancer progression that bridges the gap between metabolic reprogramming and oncogenic signaling. By activating the MAPK and VEGF pathways and suppressing apoptosis, SHMT2 creates a cellular environment conducive to tumor expansion. These findings highlight SHMT2 as a promising therapeutic target, offering a potential new avenue for treating aggressive breast cancers. Future research will focus on the precise molecular interactions that allow this mitochondrial enzyme to influence cytoplasmic signaling and the development of targeted SHMT2 inhibitors.
Summary updated